Get the Stockscreener App
0.68
2.88%
-0.0202
After Hours:
.69
0.010
+1.47%
Ocugen Inc stock is traded at $0.68, with a volume of 2.48M.
It is down -2.88% in the last 24 hours and down -9.30% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$0.7002
Open:
$0.71
24h Volume:
2.48M
Relative Volume:
0.55
Market Cap:
$197.84M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-2.5185
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
-5.28%
1M Performance:
-9.30%
6M Performance:
-47.29%
1Y Performance:
-35.85%
1-Day Range:
$0.68
$0.71
1-Week Range:
$0.6717
$0.7599
52-Week Range:
$0.6404
$2.105
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.68 | 197.84M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen to Announce Q4 and Full-Year 2024 Results with Live Webcast on March 5, 2025 - MyChesCo
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Ocugen to Host Conference Call on Wednesday, March 5, 2025 - GlobeNewswire
Ocugen, Inc. to Host Conference Call for Q4 and Full Year 2024 Financial Results on March 5, 2025 - Nasdaq
Is QuantumScape Stock a Buy Now? - The Globe and Mail
Ocugen Earnings: Can This Gene Therapy Pioneer Turn Financial Corner in 2024? - StockTitan
Ocugen, Inc. (OCGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
European Commission nods at Ocugen’s gene therapy By Investing.com - Investing.com Nigeria
Chardan Capital Reaffirms Buy Rating for Ocugen (NASDAQ:OCGN) - MarketBeat
HC Wainwright Issues Positive Forecast for Ocugen (NASDAQ:OCGN) Stock Price - MarketBeat
UPCOMING OCGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Why Ocugen (OCGN) Is Advancing Today - MSN
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen shares rise as H.C. Wainwright lifts price target to $8 - Investing.com Nigeria
Ocugen shares rise as H.C. Wainwright lifts price target to $8 By Investing.com - Investing.com South Africa
Expert Outlook: Ocugen Through The Eyes Of 4 Analysts - Benzinga
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved! - MyChesCo
Ocugen, Inc. Announces Dosing Completion in the Phase 2 - GlobeNewswire
Ocugen Completes Dosing In Phase 2 ArMaDa Trial For OCU410 In Geographic Atrophy - Nasdaq
Ocugen announces dosing completion in Phase 2 ArMaDa clinical trial - TipRanks
Ocugen Completes Phase 2 Enrollment in OCU410 Clinical Trial for Geographic Atrophy Treatment - Nasdaq
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewswire
Revolutionary One-Time Gene Therapy Outperforms Monthly Injections in Macular Degeneration Trial - StockTitan
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
What's Going On With Ocugen Stock? - MSN
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
STATE STREET CORP Reduces Stake in Ocugen Inc by 62.93% - GuruFocus.com
Nasal COVID-19 vaccine based on WashU technology to enter U.S. clinical trials - WashU Medicine
Ocugen’s OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment - MSN
Ocugen's OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment - MyChesCo
European Commission nods at Ocugen's gene therapy - Investing.com India
Ocugen Announces Positive Opinion of European Medicines - GlobeNewswire
Ocugen gets positive EU opinion for ATMP classification for OCU400 - Seeking Alpha
Ocugen Says EMA Panel Issues Positive Opinion for Potential Eye Disease Treatment - Marketscreener.com
European Commission nods at Ocugen's gene therapy By Investing.com - Investing.com Australia
Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa - Ocugen
Ocugen, Inc. Receives Positive Opinion for OCU400 Advanced Therapy Medicinal Product Classification from European Commission - Nasdaq
Revolutionary Eye Disease Gene Therapy Advances: Ocugen Secures Fast-Track Status in Europe - StockTitan
Ocugen Files Secondary Stock Shelf -January 31, 2025 at 04:44 pm EST - Marketscreener.com
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine - MSN
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):